Testosterone Prescribing and DEA Scrutiny of Men's Health Clinics

Testosterone is a Schedule III controlled substance under the Controlled Substances Act, and the men's health clinics built around testosterone replacement therapy are drawing closer DEA scrutiny of how that prescription reaches the patient. A pharmacist-in-charge who fills prescriptions for a telehealth-based men's health clinic carries the same registration, recordkeeping, and legitimate medical purpose exposure as the prescriber. A DEA finding that a clinic's prescribing pattern reflects bodybuilding or performance use rather than diagnosed hypogonadism can escalate to a DEA order to show cause or an immediate suspension order against every registration in the chain.

Testosterone's Status as a Schedule III Controlled Substance

Congress added anabolic steroids to Schedule III through the Anabolic Steroids Control Act of 1990, and the current definition at 21 U.S.C. 802(41)(A) names testosterone directly among the compounds that qualify, alongside its esters and derivatives. Schedule III status means every prescriber, pharmacy, and clinic handling testosterone injectable or pellet therapy needs an active DEA registration under 21 U.S.C. 822, issued separately for each location, a requirement covered in Separate Registration for Each Location. State controlled substance registration runs parallel to the federal requirement, a separate layer explained in State Controlled Substance Registration Running Parallel to DEA. Schedule III status also means a valid testosterone prescription must satisfy 21 CFR 1306.04: issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. That standard is what the DEA tests when it opens an inquiry into a clinic's prescribing pattern.

Telehealth Prescribing Limits for Men's Health Clinics

The Ryan Haight Act requires a prescriber to conduct at least one in-person medical evaluation before remotely prescribing a controlled substance, unless the relationship fits one of the statute's limited exceptions. DEA and HHS have extended a telemedicine flexibility that waives the in-person requirement for Schedule II through V prescribing. The current version is a fourth temporary rule effective January 1, 2026 through December 31, 2026. DEA has not finalized a permanent telemedicine special registration rule, so that temporary extension is the only lawful basis for a men's health clinic to prescribe testosterone by telehealth without a prior in-person exam. A prescription still has to satisfy the legitimate medical purpose standard regardless of exam format. The telehealth flexibility only changes how the evaluation can happen. The prescriber still has to find a legitimate medical purpose before writing the script.

Records and the Diversion-to-Bodybuilding Enforcement Theme

DEA registrants must keep dispensing and inventory records for at least two years under 21 CFR 1304.04, and those records are what an investigator reconciles when a clinic's testosterone volume looks disproportionate to its patient panel, the same inventory reconciliation exercise used across controlled substance audits. Distributors and pharmacies supplying a high-volume men's health clinic carry their own suspicious order monitoring duty to flag and report orders that depart from a normal pattern. When a prescribing pattern suggests performance enhancement or bodybuilding rather than diagnosed hypogonadism, legitimate medical purpose is the line the DEA tests, and a clinic that cannot document the diagnosis behind each prescription risks a DEA order to show cause seeking revocation, or, where DEA finds an imminent danger to public health, an immediate suspension order that cuts off dispensing before any hearing. Expired or returned testosterone inventory carries its own disposal obligation, covered in Sending Expired Controlled Substances to a Reverse Distributor, and how a clinic handles that inventory is part of the same record a DEA investigator reviews.

The DEA tests legitimate medical purpose by what the clinic's records show, not by what the patient requested or paid for.

A clinic or pharmacy that waits for the show-cause hearing to assemble its records has already lost the chance to shape the government's account during the investigation.

Why Early Legal Counsel Is Critical

It is critical that men's health clinics, prescribers, and the pharmacists who fill their prescriptions promptly retain experienced healthcare defense counsel upon receiving a DEA records request, subpoena, order to show cause, or other government inquiry. Early legal intervention can protect the registrant's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the registrant's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the registrant to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.

Health Law Alliance defends men's health clinics, prescribers, and pharmacies through DEA registration inquiries, records requests, and show-cause proceedings tied to testosterone and other controlled substance prescribing. If your clinic or pharmacy is facing a DEA inquiry into testosterone prescribing, contact Health Law Alliance for a free, confidential consultation before you respond.